Program
sacubitril
Also written as “sacubitril/valsartan”, “Experimental: Sacubitril/Allisartan and Amlodipine Group” and “AHU377”.
Its studies are mostly in Heart Failure · Essential Hypertension · Chagas Disease · Myocardial Infarction · Isolated Systolic Hypertension, led by 4 companies.
Drug pageSacubitril: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 80 open or running | phase 4since Jul 10, 2019 | Oct 5, 2007 | none ahead |
| Shenzhen Salubris Pharmaceuticalsits history only | 20 open or running | phase 3since Jul 9, 2026 | Jul 9, 2026 | none ahead |
| Viatris | 22 open or running | phase 1since Jan 25, 2024 | Jan 25, 2024 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 11 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2024First study: phase 1 study in Chronic Heart FailureFirst studyNCT06266988 · 48 planned
- Feb 14, 2024Phase 1 study in Bioequivalence StudyNCT06273254 · 48 planned · Thailand
TargetBeta
“A neprilysn (NEP) inhibitor prodrug with natriuretic activity”NCIt, by rule
“Neprilysin inhibitor”ChEMBL 37, by rule
Studies
All 2 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06273254Bioequivalence Study · Thailand | 1 | Not yet recruiting | May 2024 | 48 |
| NCT06266988Chronic Heart Failure | 1 | Not yet recruiting | Apr 2024 | 48 |
How it is read
Names in the registry
- “sacubitril/valsartan”, 5 entries
- “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
- “AHU377”, 2 entries
- “Sacubitril/valsartan”, 1 entry
- “Sacubitril and Valsartan Tablets 49mg/51mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Essential Hypertension, 2 studies
- Chagas Disease, 1 study
- Myocardial Infarction, 1 study
- Isolated Systolic Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.